A Champion’s Career in Limbo: Janibek Alimkhanuly Suspended Amid Controversy
In a shocking turn of events, undefeated middleweight champion Janibek Alimkhanuly has been handed a six-month suspension by the Kazakhstan Professional Boxing Federation (KPBF), leaving fans and critics alike divided over the circumstances. But here’s where it gets controversial: the suspension stems from a positive drug test for Meldonium, a banned substance, which Alimkhanuly claims was administered during an emergency medical treatment. Could this be a case of medical necessity clashing with strict athletic regulations? Let’s dive in.
Following a random drug test conducted by the Voluntary Anti-Doping Association (VADA), Alimkhanuly was pulled from a highly anticipated three-belt unification bout against WBA champion Erislandy Lara in December 2025. The test revealed the presence of Meldonium, a substance banned in professional sports. However, the story isn’t as straightforward as it seems. According to the KPBF’s final report, obtained exclusively by BoxingScene, Alimkhanuly ingested Meldonium as part of an emergency treatment for a transit ischemic attack (TIA) in May 2025. The medical report from the Adam Clinic in Almaty details symptoms such as severe headaches, nausea, dizziness, and limb numbness, which necessitated urgent intervention.
And this is the part most people miss: The substance in question, Meldonium, was administered under the brand name Ripronat, a medication legally prescribed in Kazakhstan but not widely recognized internationally. Alimkhanuly claims he was unaware Ripronat contained Meldonium, a substance more commonly known by its international trademark, Mildronate. This oversight led the KPBF to rule that while Alimkhanuly was negligent to a minimal degree, the medical intervention was justified, resulting in a six-month suspension rather than a more severe penalty.
The suspension, retroactive to December 2, 2025, means Alimkhanuly cannot return to the ring until June 2, 2026, at the earliest. He is also required to undergo random drug testing at his own expense and produce clean samples before resuming his career. Despite the ban, he retains his WBO middleweight title but cannot defend it until December 2, 2026. Meanwhile, the IBF is still reviewing the case, leaving the boxing world in suspense.
In the interim, the WBO has greenlit a title fight between Denzel Bentley and Endry Saveedra, scheduled for April 4, 2026, as part of the Deontay Wilder-Derek Chisora pay-per-view event in London. Alimkhanuly will be obligated to face the winner in a mandatory title consolidation bout upon his return—no exceptions. This decision highlights the WBO’s conservative approach to interim titles, a stance even more pronounced by the IBF, which has left contenders Etinosa Oliha and Shakiel Thompson in limbo.
Alimkhanuly’s journey to the top has been nothing short of remarkable. He first claimed the interim WBO middleweight title in May 2022 and was elevated to full champion later that year, successfully defending his belt five times. Three of those defenses also involved the IBF title, which he won in a stunning knockout victory over Vincenzo Gualtieri in October 2023.
Now, the question remains: Was Alimkhanuly’s suspension fair, or does it expose a gap between medical necessity and athletic regulations? Share your thoughts in the comments below. And while you’re at it, follow award-winning journalist Jake Donovan on X (https://x.com/JakeNDaBox) and Instagram (https://www.instagram.com/jakendabox_) for more insights into the world of boxing.
